Proxison

Drug Profile

Proxison

Latest Information Update: 06 Jul 2016

Price : $50

At a glance

  • Originator Antoxis
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Neurodegenerative disorders; Parkinson's disease; Stroke

Highest Development Phases

  • Preclinical Parkinson's disease; Stroke

Most Recent Events

  • 06 Jul 2016 Proxison is available for licensing as of 06 Jul 2016. http://www.antoxis.com/
  • 06 Jul 2016 Preclinical trials in Parkinson's disease in United Kingdom (unspecified route)
  • 06 Jul 2016 Preclinical trials in Stroke in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top